We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Changes in the level of serum micro RNAs in patients with psoriasis after antitumour necrosis factor-α therapy.
- Authors
Pivarcsi, A.; Meisgen, F.; Xu, N.; Ståhle, M.; Sonkoly, E.
- Abstract
Background Micro RNAs (mi RNAs) are endogenous, nonprotein-coding, regulatory RNAs with important roles in health and disease. mi RNAs are present in the circulation in a stable form and their levels are altered in diseases. Objectives To determine whether antitumour necrosis factor ( TNF)-α therapy affects serum mi RNA levels in patients with psoriasis. Methods Serum samples were obtained from healthy donors and from patients with chronic plaque psoriasis before and 12 weeks after the initiation of treatment with the TNF-inhibitor etanercept or methotrexate. mi RNA expression profiling was utilized to identify miRNAs with altered serum level in psoriasis, as well as anti- TNF-α-regulated mi RNAs in patients' sera. The expression of five miRNAs regulated by etanercept was measured by quantitative polymerase chain reaction (q PCR) in sera from patients and controls. Results Etanercept significantly suppressed a panel of 38 mi RNAs, which were found to be predominantly immune-cell derived and which have been implicated in inflammation and autoimmunity. Validation by q PCR showed that serum levels of miR-106b, mi R-26b, mi R-142-3p, mi R-223 and mi R-126 were significantly downregulated by etanercept in responders (Psoriasis Area and Severity Index change > 50%). By contrast, methotrexate did not significantly affect the levels of these miRNAs. Serum levels of these miRNAs were not upregulated in patients with psoriasis compared with healthy controls. The level of four circulating mi RNAs was significantly different (increased: mi R-128a; decreased: let-7d, miR-142-3p, miR-181a) in psoriasis and healthy serum. Conclusions The level of circulating mi RNAs is altered in psoriasis. Anti- TNF-α therapy has a profound effect on the serum level of mi RNAs; however, these are not related to disease severity. Our results suggest that changes in the mi RNA level may reflect a previously unknown effect of anti- TNF-α therapy. Our results suggest the involvement of mi RNAs in pathways affected by anti- TNF-α therapy and warrant further investigation of serum mi RNAs as potential biomarkers for therapy response in psoriasis.
- Subjects
NUCLEIC acids; PSORIASIS; SKIN diseases; TUMOR necrosis factors
- Publication
British Journal of Dermatology, 2013, Vol 169, Issue 3, p563
- ISSN
0007-0963
- Publication type
Article
- DOI
10.1111/bjd.12381